Miles Wang Launches AI Drug Startup at $2B Valuation
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Miles Wang is leaving OpenAI to launch a startup focused on AI models for drug discovery, with several other OpenAI researchers expected to join.
- Miles Wang is in talks to raise $200 million at a $2 billion valuation, with Lightspeed reportedly in discussions to lead the round.
- Chai Discovery, a two-year-old AI biotech startup co-founded by former OpenAI researcher Josh Meier, recently raised $400 million at a $3.8 billion valuation.
- Isomorphic Labs, a Google DeepMind spinout also building AI for drug discovery, secured a $2.1 billion Series B in May, signaling strong investor appetite.
- Miles Wang joined OpenAI in 2024 after leaving Harvard, where he was pursuing a computer science degree, and co-authored research on AI-automated scientific discovery.
Why it matters: AI talent and capital are rapidly converging on biotech, with Wang’s move and comparable valuations at Chai Discovery and Isomorphic Labs showing that investors now treat AI-driven drug development as a high-conviction, scalable frontier—potentially accelerating timelines for new and repurposed treatments while raising the stakes for scientific validation.
